Rubicon Research Ltd

Rubicon Research Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Wednesday, July 1, 2026, and is in preparation for the declaration of the Unaudited Financial Results (Standalone & Consolidated) for the quarter and year ending June 30, 2026. The trading window is set to reopen 48 hours after the official announcement and submission of these financial results to the stock exchanges. This measure is a standard practice to prevent insider trading during sensitive financial reporting periods.

Rubicon Research Ltd's Board of Directors approved the formulation, adoption, and implementation of the 'Rubicon Research Limited - Employees Stock Option Scheme 2026' during its meeting on May 29, 2026. The scheme allows for the grant of stock options corresponding to 24,84,415 equity shares of ₹1 each to eligible employees, subject to member and regulatory approvals. This includes 6,72,162 shares from the existing Scheme 2022. The scheme complies with SEBI (SBEB) Regulations.

Rubicon Research Ltd's board approved extending the timeline for utilizing unutilized IPO proceeds by one year, up to March 31, 2027. As of March 31, 2026, ₹3,236.46 Million of the ₹4,712.74 Million raised in the IPO had been utilized. The remaining ₹1,476.28 Million deployment is deferred due to ongoing debt repayment discussions, strategic investment vetting, and dynamic management of general corporate purposes. There is no change in the objects of the issue.

Rubicon Research Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board has recommended a dividend of ₹1.50 per equity share, subject to shareholder approval at the upcoming Annual General Meeting. The dividend will be paid within 30 days of declaration at the AGM. Deloitte Haskins & Sells LLP issued an audit report with an unmodified opinion on the financial results.

Rubicon Research Ltd has announced an earnings conference call to be held on Friday, May 29, 2026, to discuss the company's financial performance for the quarter and year ended March 31, 2026. The call will be led by Tushar Manudhane from Motilal Oswal Financial Services and will feature senior management including Mr. Parag Sancheti (CEO), Mr. Nitin Jajodia (CFO), and Mr. Sagar Oak (SVP Corp. Dev & Strategy). Dial-in details and access information have been provided for participants from India, Singapore, Hong Kong, the UK, and the USA.

Rubicon Research Ltd has announced a meeting of its Board of Directors on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend, if any, for the same period. The trading window for dealing in the company's shares has been closed since April 1, 2026, and will remain closed until 48 hours after the announcement of the financial results.

Rubicon Research Ltd has released the Monitoring Agency Report for the quarter ended March 31, 2026, as per SEBI regulations. The report, issued by India Ratings & Research Private Limited on May 15, 2026, confirms no deviation from the objects of the IPO proceeds utilization. The management has reviewed the report, which will be presented to the Audit Committee and the Board at their upcoming meetings alongside year-end financial results. The IPO included a fresh issue of ₹5,000 Million and an offer for sale of ₹8,775.00 Million.

Rubicon Research Ltd has completed the secondary acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. This follows an earlier intimation dated April 15, 2026, and was executed as per the terms of the Share Purchase Agreement. With the completion of this transaction, Arinna Lifesciences Limited is now a subsidiary of Rubicon Research Ltd.

Rubicon Research Ltd announced that its R&D facility in Concord, Ontario, Canada, underwent an unannounced USFDA inspection from April 20 to April 24, 2026. The inspection concluded successfully with no Form-483 observations issued, indicating the facility's adherence to regulatory standards. The company reiterated its commitment to maintaining high standards of compliance and quality. This positive outcome is significant for its operations in the regulated pharmaceutical market.

Rubicon Research Ltd announced that the United States Food and Drug Administration (USFDA) conducted an unannounced inspection at its R&D facility located in Concord, Ontario, Canada. The inspection took place from April 20, 2026, to April 24, 2026. The company reported that the inspection concluded without any Form-483 being issued, signifying that no objectionable conditions were found. Rubicon Research reaffirmed its commitment to maintaining the highest standards of compliance and quality.